{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T12:58:44Z","timestamp":1761310724307,"version":"3.44.0"},"reference-count":115,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.ahj.2011.06.015","type":"journal-article","created":{"date-parts":[[2011,9,10]],"date-time":"2011-09-10T23:50:27Z","timestamp":1315698627000},"page":"585-596","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Measuring and targeting aldosterone and renin in atherosclerosis\u2014A review of clinical data"],"prefix":"10.1016","volume":"162","clinical-trial-number":[{"clinical-trial-number":"nct00549757","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00853827","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01059136","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01123629","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01176968","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01259297","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Marieke A.","family":"Hillaert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eef G.","family":"Lentjes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farzin","family":"Beygui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Kemperman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Folkert W.","family":"Asselbergs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hendrik M.","family":"Nathoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierfrancesco","family":"Agostoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiel","family":"Voskuil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrice","family":"Ivanes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Jude","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel E.","family":"Bertrand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard","family":"Pasterkamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yolanda","family":"van der Graaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieter A.","family":"Doevendans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Montalescot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Van Belle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2011.06.015_bb0005","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/01.CIR.97.22.2202","article-title":"Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group","volume":"97","author":"ACE Inhibitor Myocardial Infarction Collaborative Group","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2011.06.015_bb0010","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(00)02212-1","article-title":"Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group","volume":"355","author":"Flather","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2011.06.015_bb0015","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(06)69201-5","article-title":"Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials","volume":"368","author":"Dagenais","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2011.06.015_bb0020","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.jacc.2005.11.073","article-title":"Angiotensin-converting enzyme inhibitors in coronary artery disease and preserved left ventricular systolic function: a systematic review and meta-analysis of randomized controlled trials","volume":"47","author":"Al-Mallah","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2011.06.015_bb0025","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2011.06.015_bb0030","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(08)61242-8","article-title":"Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial","volume":"372","author":"Yusuf","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2011.06.015_bb0035","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1210\/jc.2003-030490","article-title":"Williams GH. 50th anniversary of aldosterone","volume":"88","author":"Williams","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ahj.2011.06.015_bb0040","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1001\/archinte.163.10.1155","article-title":"Renin-angiotensin system and atherothrombotic disease: from genes to treatment","volume":"163","author":"Jacoby","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ahj.2011.06.015_bb0045","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1038\/ajh.2008.293","article-title":"Relationship of plasma renin with a prothrombotic state in hypertension: relevance for organ damage","volume":"21","author":"Sechi","year":"2008","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.ahj.2011.06.015_bb0050","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.atherosclerosis.2009.01.025","article-title":"Activation of MMP8 and MMP13 by angiotensin II correlates to severe intra-plaque hemorrhages and collagen breakdown in atherosclerotic lesions with a vulnerable phenotype","volume":"204","author":"Cheng","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ahj.2011.06.015_bb0055","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jvs.2006.04.033","article-title":"Angiotensin II induces histomorphologic features of unstable plaque in a murine model of accelerated atherosclerosis","volume":"44","author":"da Cunha","year":"2006","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.ahj.2011.06.015_bb0060","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1161\/01.CIR.0000127112.36796.9B","article-title":"Aldosterone enhances ischemia-induced neovascularization through angiotensin II\u2013dependent pathway","volume":"109","author":"Michel","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2011.06.015_bb0065","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1161\/01.ATV.0000178991.71605.18","article-title":"Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage","volume":"25","author":"Virmani","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ahj.2011.06.015_bb0070","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.atherosclerosis.2007.10.037","article-title":"Anti-atherosclerotic properties of telmisartan in advanced atherosclerotic lesions in apolipoprotein E deficient mice","volume":"199","author":"Blessing","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ahj.2011.06.015_bb0075","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1161\/ATVBAHA.107.139634","article-title":"Inhibition of the renin-angiotensin system abolishes the proatherogenic effect of uremia in apolipoprotein E\u2013deficient mice","volume":"27","author":"Bro","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ahj.2011.06.015_bb0080","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1161\/01.CIR.0000021122.63813.32","article-title":"Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E\u2013deficient mice","volume":"106","author":"Candido","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2011.06.015_bb0085","first-page":"565","article-title":"Evolution of angiotensin II\u2013mediated atherosclerosis in ApoE KO mice","volume":"3","author":"Cha","year":"2010","journal-title":"Mol Med Report"},{"key":"10.1016\/j.ahj.2011.06.015_bb0090","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1161\/01.CIR.0000127949.05756.9D","article-title":"Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone","volume":"109","author":"Keidar","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2011.06.015_bb0095","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1161\/01.HYP.0000140269.55873.7b","article-title":"Endogenous angiotensin II induces atherosclerotic plaque vulnerability and elicits a th1 response in ApoE\u2212\/\u2212 mice","volume":"44","author":"Mazzolai","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.ahj.2011.06.015_bb0100","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.atherosclerosis.2009.12.031","article-title":"AT1 blockade attenuates atherosclerotic plaque destabilization accompanied by the suppression of cathepsin S activity in apoE-deficient mice","volume":"210","author":"Sasaki","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ahj.2011.06.015_bb0105","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1161\/01.CIR.0000137970.47771.AF","article-title":"Inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein E\/angiotensin II type 1A receptor double-knockout mice","volume":"110","author":"Wassmann","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2011.06.015_bb0110","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0021-9150(97)00254-2","article-title":"Delapril slows the progression of atherosclerosis and maintains endothelial function in cholesterol-fed rabbits","volume":"137","author":"Hernandez","year":"1998","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ahj.2011.06.015_bb0115","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0895-7061(98)00203-9","article-title":"Comparison of the effects of AT1 receptor blockade and angiotensin converting enzyme inhibition on atherosclerosis","volume":"12","author":"Hope","year":"1999","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.ahj.2011.06.015_bb0120","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0021-9150(98)00021-5","article-title":"Induction of angiotensin converting enzyme and angiotensin II receptors in the atherosclerotic aorta of high-cholesterol fed Cynomolgus monkeys","volume":"138","author":"Song","year":"1998","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ahj.2011.06.015_bb0125","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1016\/j.jacc.2008.12.072","article-title":"Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone)","volume":"53","author":"Lonn","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2011.06.015_bb0130","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1291\/hypres.31.271","article-title":"Candesartan decreases carotid intima-media thickness by enhancing nitric oxide and decreasing oxidative stress in patients with hypertension","volume":"31","author":"Ono","year":"2008","journal-title":"Hypertens Res"},{"key":"10.1016\/j.ahj.2011.06.015_bb0135","doi-asserted-by":"crossref","first-page":"134564","DOI":"10.4061\/2010\/134564","article-title":"Impact of medical therapy on atheroma volume measured by different cardiovascular imaging modalities","volume":"2010","author":"Sinno","year":"2010","journal-title":"Cardiol Res Pract"},{"key":"10.1016\/j.ahj.2011.06.015_bb0140","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1161\/01.STR.0000227223.90239.13","article-title":"Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials","volume":"37","author":"Wang","year":"2006","journal-title":"Stroke"},{"key":"10.1016\/j.ahj.2011.06.015_bb0145","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/hr.2010.237","article-title":"The effect of losartan and amlodipine on left ventricular diastolic function and atherosclerosis in Japanese patients with mild-to-moderate hypertension (J-ELAN) study","volume":"34","author":"Yamamoto","year":"2011","journal-title":"Hypertens Res"},{"key":"10.1016\/j.ahj.2011.06.015_bb0150","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0002-9149(00)01399-0","article-title":"Effect of quinapril on intimal hyperplasia after coronary stenting as assessed by intravascular ultrasound","volume":"87","author":"Kondo","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2011.06.015_bb0155","first-page":"205","article-title":"The CAIRP (CAndesartan for In-stent Restenosis Prevention) Trial\u2014a multicenter study of AT1-receptor blocker therapy in coronary stenting","volume":"20","author":"Kramer","year":"2008","journal-title":"J Invasive Cardiol"},{"key":"10.1016\/j.ahj.2011.06.015_bb0160","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.ahj.2006.07.003","article-title":"A double-blind, randomized, placebo-controlled multicenter clinical trial to evaluate the effects of the angiotensin II receptor blocker candesartan cilexetil on intimal hyperplasia after coronary stent implantation","volume":"152","author":"Radke","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2011.06.015_bb0165","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.ahj.2004.08.006","article-title":"The angiotensin II receptor blocker candesartan cilexetil reduces neointima proliferation after coronary stent implantation: a prospective randomized study under intravascular ultrasound guidance","volume":"149","author":"Yoshida","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2011.06.015_bb0170","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.amjcard.2007.02.073","article-title":"Long-term effect of perindopril on coronary atherosclerosis progression (from the PERindopril's Prospective Effect on Coronary aTherosclerosis by Angiography and IntraVascular Ultrasound Evaluation [PERSPECTIVE] Study)","volume":"100","author":"Rodriguez-Granillo","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2011.06.015_bb0175","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1093\/eurheartj\/ehm255","article-title":"Effect of perindopril on coronary remodelling: insights from a multicentre, randomized study","volume":"28","author":"Rodriguez-Granillo","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2011.06.015_bb0180","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.jacc.2009.09.062","article-title":"Impact of olmesartan on progression of coronary atherosclerosis: a serial volumetric intravascular ultrasound analysis from the OLIVUS (Impact of OLmesarten on progression of coronary atherosclerosis: evaluation by IntraVascular UltraSound) Trial","volume":"55","author":"Hirohata","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2011.06.015_bb0185","doi-asserted-by":"crossref","DOI":"10.2165\/00003495-200565080-00004","article-title":"Angiotensin antagonism in coronary artery disease: results after coronary revascularisation","volume":"65","author":"Ribichini","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.ahj.2011.06.015_bb0190","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1136\/bmj.1.5292.1569","article-title":"Effects of angiotensin infusions on aldosterone and electrolyte excretion in normal subjects and patients with hypertension and adrenocortical disorders","volume":"1","author":"Biron","year":"1962","journal-title":"Br Med J"},{"key":"10.1016\/j.ahj.2011.06.015_bb0195","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jama.1960.03030030014003","article-title":"Hypotensive agents and pressor substances: the effect of epinephrine, norepinephrine, angiotensin II, and others on the secretory rate of aldosterone in man","volume":"174","author":"Laragh","year":"1960","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2011.06.015_bb0200","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1161\/01.RES.11.1.171","article-title":"Relation of renin and angiotensin II to the control of aldosterone secretion","volume":"11","author":"Davis","year":"1962","journal-title":"Circ Res"},{"key":"10.1016\/j.ahj.2011.06.015_bb0205","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1111\/j.1440-1681.1998.tb02300.x","article-title":"Aldosterone action: fact, failure and the future","volume":"25","author":"Funder","year":"1998","journal-title":"Clin Exp Pharmacol Physiol Suppl"},{"key":"10.1016\/j.ahj.2011.06.015_bb0210","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1172\/JCI104436","article-title":"Stimulation of active sodium transport by the isolated toad bladder with aldosterone in vitro","volume":"40","author":"Crabbe","year":"1961","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ahj.2011.06.015_bb0215","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1073\/pnas.50.6.1169","article-title":"On the mechanism of action of aldosterone on sodium transport: the role of protein synthesis","volume":"50","author":"Edelman","year":"1963","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ahj.2011.06.015_bb0220","doi-asserted-by":"crossref","first-page":"24316","DOI":"10.1016\/S0021-9258(19)51084-5","article-title":"Vascular aldosterone. Biosynthesis and a link to angiotensin II\u2013induced hypertrophy of vascular smooth muscle cells","volume":"269","author":"Hatakeyama","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ahj.2011.06.015_bb0225","doi-asserted-by":"crossref","first-page":"4796","DOI":"10.1210\/en.2004-0295","article-title":"Origin of aldosterone in the rat heart","volume":"145","author":"Gomez-Sanchez","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.ahj.2011.06.015_bb0230","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1210\/en.2004-0081","article-title":"Do human vascular endothelial cells produce aldosterone?","volume":"145","author":"Ahmad","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.ahj.2011.06.015_bb0235","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1161\/01.CIR.92.2.175","article-title":"Prerequisite for cardiac aldosterone action: mineralocorticoid receptor and 11\u0304-hydroxysteroid dehydrogenase in the human heart","volume":"92","author":"Lombes","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2011.06.015_bb0240","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1046\/j.1523-1755.2003.00929.x","article-title":"Aldosterone\/salt induces renal inflammation and fibrosis in hypertensive rats","volume":"63","author":"Blasi","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.ahj.2011.06.015_bb0245","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1161\/CIRCULATIONAHA.104.521625","article-title":"Aldosterone synthase inhibitor ameliorates angiotensin II\u2013induced organ damage","volume":"111","author":"Fiebeler","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2011.06.015_bb0250","doi-asserted-by":"crossref","first-page":"H1802","DOI":"10.1152\/ajpheart.01096.2001","article-title":"Aldosterone induces a vascular inflammatory phenotype in the rat heart","volume":"283","author":"Rocha","year":"2002","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.ahj.2011.06.015_bb0255","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1161\/01.HYP.0000023182.68420.EB","article-title":"Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism","volume":"40","author":"Rossi","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.ahj.2011.06.015_bb0260","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1161\/01.ATV.0000204635.75748.0f","article-title":"Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation","volume":"26","author":"Suzuki","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ahj.2011.06.015_bb0265","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1161\/01.RES.0000159937.05502.d1","article-title":"Angiotensin II and aldosterone regulate gene transcription via functional mineralocorticoid receptors in human coronary artery smooth muscle cells","volume":"96","author":"Jaffe","year":"2005","journal-title":"Circ Res"},{"key":"10.1016\/j.ahj.2011.06.015_bb0270","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1210\/en.2006-1438","article-title":"Early aldosterone-regulated genes in cardiomyocytes: clues to cardiac remodeling?","volume":"148","author":"Fejes-Toth","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.ahj.2011.06.015_bb0275","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0002-9440(10)64454-9","article-title":"Aldosterone-induced inflammation in the rat heart: role of oxidative stress","volume":"161","author":"Sun","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ahj.2011.06.015_bb0280","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1161\/01.HYP.0000034738.79310.06","article-title":"Spironolactone improves angiotensin-induced vascular changes and oxidative stress","volume":"40","author":"Virdis","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.ahj.2011.06.015_bb0285","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1042\/cs1030425","article-title":"Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy","volume":"103","author":"Farquharson","year":"2002","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.ahj.2011.06.015_bb0290","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.CIR.101.6.594","article-title":"Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I\/angiotensin II conversion in patients with chronic heart failure","volume":"101","author":"Farquharson","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2011.06.015_bb0295","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1161\/01.HYP.0000171479.36880.17","article-title":"Participation of prostacyclin in endothelial dysfunction induced by aldosterone in normotensive and hypertensive rats","volume":"46","author":"Blanco-Rivero","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.ahj.2011.06.015_bb0300","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1161\/01.CIR.0000015854.60710.10","article-title":"Mineralocorticoid receptor antagonism in experimental atherosclerosis","volume":"105","author":"Rajagopalan","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2011.06.015_bb0305","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/01.HYP.0000184640.81730.22","article-title":"Eplerenone inhibits atherosclerosis in nonhuman primates","volume":"46","author":"Takai","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.ahj.2011.06.015_bb0310","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0008-6363(96)88542-7","article-title":"Neointimal thickening after balloon denudation is enhanced by aldosterone and inhibited by spironolactone, and aldosterone antagonist","volume":"29","author":"Van Belle","year":"1995","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ahj.2011.06.015_bb0315","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1097\/00005344-200306000-00019","article-title":"Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E\u2013deficient mice","volume":"41","author":"Keidar","year":"2003","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.ahj.2011.06.015_bb0320","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1097\/01.hjh.0000182527.52063.32","article-title":"The regressive effect of an angiotensin II receptor blocker on formed fatty streaks in monkeys fed a high-cholesterol diet","volume":"23","author":"Takai","year":"2005","journal-title":"J Hypertens"},{"key":"10.1016\/j.ahj.2011.06.015_bb0325","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1161\/HYPERTENSIONAHA.107.104299","article-title":"Addition of eplerenone to an angiotensin-converting enzyme inhibitor effectively improves nitric oxide bioavailability","volume":"51","author":"Imanishi","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.ahj.2011.06.015_bb0330","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1161\/CIRCRESAHA.109.196576","article-title":"Aldosterone-induced activation of signaling pathways requires activity of angiotensin type 1a receptors","volume":"105","author":"Lemarie","year":"2009","journal-title":"Circ Res"},{"key":"10.1016\/j.ahj.2011.06.015_bb0335","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1161\/01.CIR.104.2.137","article-title":"Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes","volume":"104","author":"Harada","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2011.06.015_bb0340","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1161\/01.RES.0000180753.63183.95","article-title":"Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells","volume":"97","author":"Min","year":"2005","journal-title":"Circ Res"},{"key":"10.1016\/j.ahj.2011.06.015_bb0345","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1210\/en.2004-1674","article-title":"Aldosterone induces angiotensin converting enzyme gene expression via a JAK2-dependent pathway in rat endothelial cells","volume":"146","author":"Sugiyama","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.ahj.2011.06.015_bb0350","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1161\/01.HYP.0000140771.21243.ed","article-title":"Mechanism for aldosterone potentiation of angiotensin II\u2013stimulated rat arterial smooth muscle cell proliferation","volume":"44","author":"Xiao","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.ahj.2011.06.015_bb0355","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1161\/CIRCULATIONAHA.106.668715","article-title":"Aldosterone and cardiovascular disease: smoke and fire","volume":"114","author":"Calhoun","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2011.06.015_bb0360","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1161\/01.CIR.82.5.1730","article-title":"Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group","volume":"82","author":"Swedberg","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2011.06.015_bb0365","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1053\/euhj.1998.1093","article-title":"Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study","volume":"19","author":"Vantrimpont","year":"1998","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2011.06.015_bb0370","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/0735-1097(94)90001-9","article-title":"Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril","volume":"24","author":"Rouleau","year":"1994","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2011.06.015_bb0375","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ehj.2003.10.030","article-title":"The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT","volume":"25","author":"Latini","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2011.06.015_bb0380","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1161\/CIRCULATIONAHA.106.653964","article-title":"Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure","volume":"115","author":"Guder","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2011.06.015_bb0385","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1161\/CIRCULATIONAHA.106.634626","article-title":"High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction","volume":"114","author":"Beygui","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2011.06.015_bb0390","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.ahj.2008.12.013","volume":"157","author":"Beygui","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2011.06.015_bb0395","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1093\/eurheartj\/ehn383","article-title":"Plasma aldosterone levels during hospitalization are predictive of survival post-myocardial infarction","volume":"29","author":"Palmer","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2011.06.015_bb0400","article-title":"Aldosterone, mortality and acute ischemic events in patients with coronary artery disease outside the setting of acute MI or heart failure","author":"Ivanes","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2011.06.015_bb0405","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1093\/eurheartj\/ehq019","article-title":"Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study","volume":"31","author":"Tomaschitz","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2011.06.015_bb0410","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/ncpneph0575","article-title":"The incidence and implications of aldosterone breakthrough","volume":"3","author":"Bomback","year":"2007","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1016\/j.ahj.2011.06.015_bb0415","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2011.06.015_bb0420","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2011.06.015_bb0425","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jacc.2005.04.038","article-title":"Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure","volume":"46","author":"Pitt","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2011.06.015_bb0430","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2011.06.015_bb0435","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1161\/01.CIR.0000134791.68010.FA","volume":"110","author":"Antman","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2011.06.015_bb0440","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/eurheartj\/ehi204","article-title":"Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology","volume":"26","author":"Swedberg","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2011.06.015_bb0445","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.108.778811","article-title":"Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)","volume":"118","author":"Pitt","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2011.06.015_bb0450","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJM197203022860901","article-title":"Essential hypertension: renin and aldosterone, heart attack and stroke","volume":"286","author":"Brunner","year":"1972","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2011.06.015_bb0455","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0021-9150(77)90022-3","article-title":"Plasma renin activity in men with relation to the presence of ischaemic heart disease","volume":"27","author":"Slaby","year":"1977","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ahj.2011.06.015_bb0460","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJM199104183241605","article-title":"Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension","volume":"324","author":"Alderman","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2011.06.015_bb0465","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0895-7061(96)00301-9","article-title":"Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients","volume":"10","author":"Alderman","year":"1997","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.ahj.2011.06.015_bb0470","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJM199308263290905","article-title":"Plasma renin activity and ischemic heart disease","volume":"329","author":"Meade","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2011.06.015_bb0475","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1056\/NEJMoa055373","article-title":"Multiple biomarkers for the prediction of first major cardiovascular events and death","volume":"355","author":"Wang","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2011.06.015_bb0480","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1093\/eurheartj\/ehm399","article-title":"Plasma renin and risk of cardiovascular disease and mortality: the Framingham Heart Study","volume":"28","author":"Parikh","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2011.06.015_bb0485","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/0002-9149(89)90579-1","article-title":"Long-term predictors of sudden and low output death in chronic congestive heart failure secondary to coronary artery disease","volume":"64","author":"Rockman","year":"1989","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2011.06.015_bb0490","first-page":"VI40","article-title":"Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group","volume":"87","author":"Francis","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2011.06.015_bb0495","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1161\/01.CIR.94.4.690","article-title":"Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction","volume":"94","author":"Benedict","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2011.06.015_bb0500","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1253\/circj.71.915","article-title":"Comparison of active renin concentration and plasma renin activity as a prognostic predictor in patients with heart failure","volume":"71","author":"Tsutamoto","year":"2007","journal-title":"Circ J"},{"key":"10.1016\/j.ahj.2011.06.015_bb0505","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1161\/CIRCULATIONAHA.104.525527","article-title":"Prediction of myocardial infarction by N-terminal-pro-B-type natriuretic peptide, C-reactive protein, and renin in subjects with cerebrovascular disease","volume":"112","author":"Campbell","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2011.06.015_bb0510","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.amjcard.2010.04.040","article-title":"Relation of elevated plasma renin activity at baseline to cardiac events in patients with angiographically proven coronary artery disease","volume":"106","author":"Muhlestein","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2011.06.015_bb0515","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehr066","article-title":"Plasma renin activity predicts cardiovascular mortality in the Heart Outcomes Prevention Evaluation (HOPE) study","author":"Verma","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2011.06.015_bb0520","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1084\/jem.106.3.439","article-title":"The preparation, purification, and amino acid sequence of a polypeptide renin substrate","volume":"106","author":"Skeggs","year":"1957","journal-title":"J Exp Med"},{"key":"10.1016\/j.ahj.2011.06.015_bb0525","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1097\/HJH.0b013e3283310f92","article-title":"Renal and cardio-protective effects of direct renin inhibition: a systematic literature review","volume":"27","author":"Heerspink","year":"2009","journal-title":"J Hypertens"},{"key":"10.1016\/j.ahj.2011.06.015_bb0530","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2165\/00003495-200767120-00008","article-title":"Aliskiren: a review of its use in the management of hypertension","volume":"67","author":"Frampton","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.ahj.2011.06.015_bb0535","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/1470320309104662","article-title":"Managing cardiovascular and renal risk: the potential of direct renin inhibition","volume":"10","author":"Sever","year":"2009","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.ahj.2011.06.015_bb0540","doi-asserted-by":"crossref","first-page":"971","DOI":"10.2147\/VHRM.S3215","article-title":"The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction","volume":"4","author":"Verdecchia","year":"2008","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.ahj.2011.06.015_bb0545","first-page":"984","article-title":"Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice","volume":"118","author":"Lu","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ahj.2011.06.015_bb0550","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1161\/HYPERTENSIONAHA.108.110932","article-title":"Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine","volume":"51","author":"Nussberger","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.ahj.2011.06.015_bb0555","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s00395-010-0120-5","article-title":"The renin inhibitor aliskiren upregulates pro-angiogenic cells and reduces atherogenesis in mice","volume":"105","author":"P\u00f6ss","year":"2010","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.ahj.2011.06.015_bb0560","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1161\/HYPERTENSIONAHA.108.111120","article-title":"Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes","volume":"52","author":"Imanishi","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.ahj.2011.06.015_bb0565","unstructured":"clinicaltrials.gov. 3-4-2011. 3-4-2011. Ref Type: Internet Communication."},{"key":"10.1016\/j.ahj.2011.06.015_bb0570","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1373\/clinchem.2008.118000","article-title":"Activity assays and immunoassays for plasma renin and prorenin: information provided and precautions necessary for accurate measurement","volume":"55","author":"Campbell","year":"2009","journal-title":"Clin Chem"},{"key":"10.1016\/j.ahj.2011.06.015_bb0575","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1097\/HJH.0b013e3282f6a671","article-title":"Newly developed renin and prorenin assays and the clinical evaluation of renin inhibitors","volume":"26","author":"Schalekamp","year":"2008","journal-title":"J Hypertens"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870311004856?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870311004856?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:45:40Z","timestamp":1757569540000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870311004856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":115,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0002870311004856"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2011.06.015","relation":{},"ISSN":["0002-8703"],"issn-type":[{"type":"print","value":"0002-8703"}],"subject":[],"published":{"date-parts":[[2011,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Measuring and targeting aldosterone and renin in atherosclerosis\u2014A review of clinical data","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2011.06.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}